Skip to content

Sutro Biopharma STRO Shares (Diluted)

Shares (Diluted) at other companies

Pfizer logo
PfizerPFE
5.7B+0.4%
Gilead Sciences logo
Gilead SciencesGILD
1.3B-0.4%
Regenxbio logo
RegenxbioRGNX
52.4M+1.9%
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
23.4M+17.4%
Xencor logo
XencorXNCR
75.2M+2.1%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
28.7M-6.4%

Other financials

Income statement

See full
Revenue$14.5M-16.5%
Operating income-$29.7M+56.7%
Net income-$38.5M+49.3%
EPS (diluted)-$2.94+67.6%

Balance sheet

See full
Cash & equivalents$73.7M-30.6%
Total debt$13.6M-36.3%
Total equity-$66.9M-159%
Total assets$242.0M-24.7%

Cash flow

See full
Operating cash flow-$42.3M+37.7%
CapEx--100%
Free cash flow-$42.3M+37.8%

Valuation

See full
Market cap$489.66M+624%
Enterprise value$429.61M-2,600%
P/S4.9×+3.9×

Profitability

See full
Operating margin-120%-48.6pp
Net margin-154.2%-56.7pp
FCF margin-152.2%-51.1pp

Returns & leverage

See full
Return on equity-234.2%
Debt / equity0.5×+0.3×
Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sutro Biopharma's shares (diluted)?
Sutro Biopharma (STRO) reported shares (diluted) of 13.1M in Q1 2026.
How has Sutro Biopharma's shares (diluted) changed year-over-year?
Sutro Biopharma's shares (diluted) increased by 56.4% year-over-year, from 8.4M to 13.1M.
What is the long-term trend for Sutro Biopharma's shares (diluted)?
Over 4 years (2021 to 2025), Sutro Biopharma's shares (diluted) has grown at a 0.3% compound annual growth rate (CAGR), from 184.3M to 186.3M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.